QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VistaGen Therapeutics, Inc. (VSTA) Turns Back Time To Give Once-Promising Drug Candidates A Second Chance 0 comments
    Nov 14, 2013 10:02 AM | about stocks: VTGN

    VistaGen Therapeutics, a biotechnology company, is blazing new trails by looking to the past. The company has developed a pioneering stem cell technology platform that can give a second chance to potentially lifesaving drugs that have been shelved during human trials - essentially turning back the clock for stymied drug candidates and giving them a new pathway to success.

    Human Clinical Trials in a Test Tube is VistaGen's revolutionary human pluripotent stem cell (hPSC) technology platform, offering the pharmaceutical world a gateway through which formerly discontinued drug development candidates can potentially make a comeback. The platform surpasses animal testing and other nonclinical techniques and technologies currently being used in drug development. These presently used methods can only approximate human biology in their attempts to predict the outcomes of a drug candidate, which has spelled disaster and a dead end for countless drug candidates when they reached human trials.

    Pharmaceutical companies spend years and millions of dollars developing drugs that show great therapeutic and commercial potential in preclinical development, only to have them fail at the human trial stage because of unanticipated heart or liver toxicity or metabolism issues in human subjects. That fast, a massive investment goes down the drain and the world loses a potentially lifesaving and life-altering drug. But with Human Clinical Trials in a Test Tube, VistaGen can potentially change all that.

    Human Clinic Trials in a Test Tube overleaps the limitations of animal and in vitro cell testing and offers a predictive toxicology screening system which much more closely emulates human biology early in the drug development process - long before real human subjects ever encounter the drug. Using this hPSC technology, VistaGen can not only help pharmaceutical companies experience greater success in their drug development efforts, but the company will be able to create its own diverse pipeline of new, proprietary drug rescue variants of discontinued small molecule candidates that were ultimately discontinued due to adverse reactions in human test subjects.

    VistaGen intends to get a valuable head start in identifying and developing new, safe drug rescue variants by focusing on these once-promising discontinued drug candidates. The company will not only resurrect potentially revolutionary drug candidates - it will save a great deal of time and money on its journey to bring new drugs to market.

    For more information, visit VistaGen.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: VTGN
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.